Navigation Links
OrbusNeich Announces Favorable Ruling From the European Patent Office
Date:2/12/2013

FORT LAUDERDALE, Fla., Feb. 12, 2013 /PRNewswire/ -- OrbusNeich Medical, Inc. ("OrbusNeich") announced that it received a favorable ruling from the European Patent Office ("EPO") yesterday in connection with its European Patent EP1 341 482. The '482 patent covers certain novel stents with helical structures.  It was issued by the EPO to OrbusNeich in October 2010 and does not expire until December 2021.  

In July 2011, Boston Scientific Corporation (NYSE: BSX) and Terumo Kabushiki Kaisha filed oppositions asking the EPO to revoke the '482 patent, asserting that the patent was invalid.  In response, OrbusNeich amended the claim of the '482 patent to more clearly identify the scope of its novel, helical stents.  During oral proceedings held yesterday in The Hague, the EPO upheld the claim of the '482 patent as amended.  

OrbusNeich believes that the claim of the '482 patent is infringed by current lines of Boston Scientific's stent systems.  OrbusNeich is committed to maintaining and enforcing patent protection for all of its intellectual property and innovations.  The Company is evaluating all options related to its stent patent portfolio.   

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous™ Stent, as well as other stents and balloons marketed under the names of Azule™, R stent™, Scoreflex™, Sapphire™, Sapphire II™ and Sapphire NC™. Development stage products include the COMBO Dual Therapy Stent™, the world's first dual therapy stent. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich, and learn more about the company and its innovative technology on OrbusNeich's YouTube Channel: http://www.youtube.com/user/OrbusNeichMedia.

Global Media Contacts:
Dan Katcher / Jamie Moser
Joele Frank , Wilkinson Brimmer Katcher
(212) 355-4449


'/>"/>
SOURCE OrbusNeich Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Early Coronary Artery Healing Advantage of OrbusNeichs Combo Dual Therapy Stent™ Compared to the TAXUS® Stent Shown in Two Clinical Trial Subgroup Analyses
2. Trovagene Announces Commercial Launch Timelines for HPV Carrier and Oncogene Mutation Tests
3. Comprehensive Care Corporation Announces New Medicare Contract with Humana Health Plan of California, Inc.
4. Unilife Corporation Announces Financial Results For Fiscal Year 2013 Second Quarter
5. Regeneron Announces Receipt of Hart-Scott-Rodino Notice
6. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
7. Depomed Announces Appointment of Vicente J. Anido, Jr., Ph.D. to Board of Directors, and Retirement of Directors Julian N. Stern and Craig R. Smith, M.D.
8. CPhI Announces its 2nd Annual Global Pharma Regulatory Summit
9. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
10. NASP Announces Partnership with Gerry Crocker to Advance Specialty Pharmacy Industry
11. American Outcomes Management, L.P. announces the appointment of Patrick S. Smith as President and Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ORANGE COUNTY, Calif. , May 4, 2016  It,s time for an upgrade. ... interface shown on a brilliant 3.5 inch LCD, the illustrious DVMAXX HD  offers ... top brands as well as a world class manufacturer of innovative technology.  ... ... ...
(Date:5/4/2016)... Jersey , May 4, 2016 ... successful completion of an alternative public offering (APO). This ... owned operating company, Valeritas, Inc. and a private placement ... stock at $5.00 per share. Under the ... May 3, 2016, Valeritas Holdings, Inc. will trade on ...
(Date:5/4/2016)... May 4, 2016 ... the  "Global Acute lymphocytic Leukemia Market and ... their offering.       (Logo: ... Lymphocytic Leukemia Market and Competitive Landscape Highlights ... Leukemia pipeline products, Acute Lymphocytic Leukemia epidemiology, ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... , ... TransWipe Volume 3 is a set of 30 professional transition animations ... between two video clips to instantly add a unique transition to any Final Cut ... and orientation options. TransWipe Volume 3 is a Final Cut Pro X exclusive plugin. ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... While the ... being paid to the impact our aging population has on communities and resources. Aging ... adults plan for and face age-related challenges. , Aging Life Care is a ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... overall select performance in the industry’s gold standard KLAS Performance Report, ... Epic Consulting report assessed organizations that specialize in consulting services for electronic health ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... long-acting injectables (LAIs), today announced a development collaboration with the Australian critical ... serious mental disorders such as schizophrenia. , LAI medicines can offer improved therapeutic ...
(Date:5/5/2016)... ... 05, 2016 , ... Textile Exchange is excited to announce the ... review. The stakeholder review is an important opportunity for interested parties to give input ... to the wool industry., The RWS is intended to be a global benchmark for ...
Breaking Medicine News(10 mins):